Evidence map›Paper›PMID 40685401›Full record

Observational studyNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational study.

Marco Bolchini, Giulia Ceccardi, Francesca Schiano di Cola, Michele Di Pasquale, Renata Rao, Alessandro Padovani

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marco BolchiniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. marco.bolchini1@gmail.com.ORCID http://orcid.org/0000-0002-5161-5545
Giulia CeccardiNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Francesca Schiano di ColaNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Michele Di PasqualeNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Renata RaoNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Alessandro PadovaniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMigraine is frequently associated with psychiatric comorbidities, especially anxiety and depressive disorders, with related worse clinical outcome and chronicisation. Aim of the study was to assess the effectiveness of anti-CGRP antibodies in alleviating migraine-related symptoms and comorbid anxiety and depressive symptoms.

methodsRetrospective observational study including 206 migraine out-patients in treatment with anti-CGRP antibodies. Beck Depression Inventory (BDI) scale assessing depressive symptoms and Zung Anxiety Scale rating anxiety manifestations, were adopted. Patients were divided into two groups based on the severity of mood disturbances according to BDI score. Effectiveness outcomes (monthly headache days (MHDs), monthly migraine days (MMDs), analgesic consumption, Numerical Rating Scale (NRS), Migraine Disability Assessment (MIDAS) score, Headache Impact Test (HIT-6) score) and self-assessment anxiety and depression scales (BDI, Zung) were analysed after 3 and 6 months of treatment.

resultsEffectiveness outcomes showed a significant clinical improvement at T3 (ΔMHD - 9.99 ± 7.82 in Group 1, -10.82 ± 7.62 in Group 2) and T6 (MHD - 10.30 ± 7.41 in Group 1, -10.61 ± 7.87 in Group 2), irrespective of the presence of associated mood symptoms. Treatment resulted in a notable improvement in anxiety and depressive manifestations, with significant reduction in BDI and Zung scales at T3 (ΔBDI - 1.30 ± 3.74 in Group 1, -6.35 ± 11.34 in Group 2) and T6 (ΔBDI - 1.67 ± 4.77 in Group 1, -8.06 ± 10.35 in Group 2).

conclusionsThis study corroborates the effectiveness of anti-CGRP antibody treatment in migraine patients, irrespective of the presence of comorbid mood-related symptoms. Furthermore, the persistently favourable outcome in mood symptom severity and intensity throughout the course of treatment substantiates the beneficial impact of this therapeutic approach.

Indexed as

Antibodies, MonoclonalMigraine DisordersMood DisordersAdultFemaleHumansMaleMiddle AgedPsychiatric Status Rating ScalesRetrospective StudiesTreatment OutcomeAntibodies, MonoclonalAnti-CGRP monoclonal antibodiesAnxiety disordersCGRPDepressive disordersMigraineMood disorders

Identifiers

PMID40685401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.